Cytek Biosciences

Cytek Biosciences FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cytek Biosciences (CTKB) as of Nov 1, 2026 is 13.18 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -363.02 % — a change of -103.63% (higher).

FCF Conversion

13.18 %

YoY

-103.63%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cytek Biosciences is 2025 13.18 % . FCF Conversion Rate (FCF/EBITDA) of Cytek Biosciences was 2024 -363.02 % . It decreases by -103.63% higher compared to the previous year.

The Cytek Biosciences FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
87.48 USD
Jan 1, 2020
70.11 USD
Jan 1, 2021
8.86 USD
Jan 1, 2022
-857.88 USD
Jan 1, 2023
-3.74 USD
Jan 1, 2024
-363.02 USD
Jan 1, 2025
13.18 USD
The Cytek Biosciences FCF Conversion history
YEARFCF ConversionYoY
13.18 %-103.63%
-363.02 %+9,613.67%
-3.74 %-99.56%
-857.88 %-9,778.57%
8.86 %-87.36%
70.11 %-19.85%
87.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytek Biosciences Stock analysis

What does Cytek Biosciences do? Cytek Biosciences is a leading company in the cell analysis industry, offering advanced hardware and software-based solutions for biological research and diagnostics. The company was founded in 2011 by Dr. Wenbin Jiang and is headquartered in Fremont, California. The origins of Cytek can be traced back to 2002 when Jiang co-founded the company Dako Cytomation with Dr. Frank Fan. The company developed and produced products for cell analysis, including a new generation of cell counters and sorters. In 2010, Dako Cytomation was acquired by Agilent Technologies, and Jiang saw an opportunity to further expand his business model. In 2011, Jiang founded Cytek Biosciences with the aim of bringing a new generation of cell counters and sorters to the market that improve the performance and affordability of existing systems. With the acquisition of Now Bio in 2014, the company expanded its focus on developing new instruments and applications that can enhance the precision and efficiency of cell analysis. Cytek Biosciences primarily focuses on selling cell counters and sorters. In addition, the company also offers support services such as maintenance, repair, and training to ensure that customers can safely and effectively use their products. The customers of Cytek are primarily academic institutions, biotech companies, pharmaceutical companies, and government agencies involved in biological research and development. Cytek's products provide these customers with a powerful and cost-effective method of analyzing and sorting cells, increasing the efficiency and accuracy of their research work. Cytek Biosciences has several product lines tailored to different applications and customer needs. These include the Cytek Aurora, a complete spectral flow cytometer platform that can measure up to 50 channels simultaneously; the Cytek Northern Lights, a cost-effective spectral flow cytometer platform for cell analysis suitable for basic research and high-throughput screening; and the Cytek DxP Athena, a high-throughput sorting system that offers fast sorting speed and reduces the risk of cell damage and loss. In addition to these product lines, Cytek also offers a range of services including customer training, application development and support, as well as customer service and maintenance services for its products. In summary, Cytek Biosciences is a leading company in the field of cell analysis. It specializes in the development of cell counters and sorters that generate data with higher resolution and precision to enhance efficiency and accuracy in biological research and diagnostics. The company offers a variety of products and services to meet the needs of its customers. Cytek Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytek Biosciences stock

FCF Conversion Rate (FCF/EBITDA) of Cytek Biosciences is 13.18 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Cytek Biosciences changed from -363.02 % to 13.18 %, representing a -103.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cytek Biosciences since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cytek Biosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cytek Biosciences

All Key Metrics — Cytek Biosciences